The preparation of porcine circovirus type 2 (PCV2) virus-like particles using a recombinant pseudorabies virus and its application to vaccine development

Journal of Biotechnology

Volumn 181, Issue , 2014, Pages 12-19

  Chi, Jyun Ni ^a   Wu, Ching Ying ^a   Chien, Maw Sheng ^a   Wu, Pei Ching ^a   Wu, Chi Ming ^a   Huang, Chienjin ^a  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

Porcine circovirus type 2; Pseudorabies virus; Subunit vaccine; Virus like particles

Indexed keywords

GENES; PROTEINS; VACCINES;

ANTIBODY RESPONSE; HOMOLOGOUS RECOMBINATION; PORCINE CIRCOVIRUS TYPE 2; STRUCTURAL PROTEINS; SUBUNIT VACCINE; VACCINE DEVELOPMENT; VIRUS REPLICATION; VIRUS-LIKE PARTICLES;

VIRUSES;

CAP PROTEIN; MARKER VACCINE; NEUTRALIZING ANTIBODY; OLIGONUCLEOTIDE; PORCINE CIRCOVIRUS TYPE 2 VACCINE; STRUCTURAL PROTEIN; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CIRCOVIRUS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMOLOGOUS RECOMBINATION; IMMUNOFLUORESCENCE; IMMUNOGENICITY; MOUSE; NONHUMAN; PORCINE CIRCOVIRUS TYPE 2; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDORABIES HERPETOVIRUS; RESTRICTION SITE; TRANSMISSION ELECTRON MICROSCOPY; VACCINATION; VIRUS CAPSID; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS VIRULENCE; WESTERN BLOTTING; ANIMAL; CHEMISTRY; GENETICS; SWINE; VIRION; VIROLOGY;

ANIMALS; CIRCOVIRUS; HERPESVIRUS 1, SUID; MICE; SWINE; VACCINES, SYNTHETIC; VIRION;

EID: 84899628880     PISSN: 01681656     EISSN: 18734863     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2014.04.006     Document Type: Article

References (30)

1. Alarcon P., Wieland B., Mateus A.L., Dewberry C. Pig farmers' perceptions, attitudes, influences and management of information in the decision-making process for disease control. Prev. Vet. Med. 2013, http://dx.doi.org/10.1016/j.prevetmed.2013.08.004.
2. Allan G.M., Kennedy S., McNeilly F., Foster J.C., Ellis J.A., Krakowka S.J., Meehan B.M., Adair B.M. Experimental reproduction of severe wasting disease by co-infection of pigs with porcine circovirus and porcine parvovirus. J. Comp. Pathol. 1999, 121:1-11.
3. Allan G.M., Ellis J.A. Porcine circoviruses: a review. J. Vet. Diagn. Invest. 2000, 12:3-14.
4. Allan G.M., McNeilly F., Kennedy S., Meehan B., Ellis J., Krakowka S. Immunostimulation, PCV-2 and PMWS. Vet. Rec. 2000, 147:170-171.
5. Chae C. Commercial porcine circovirus type 2 vaccines: efficacy and clinical application. Vet. J. 2012, 194:151-157.
6. Chen Y., Guo W., Xu Z., Yan Q., Luo Y., Shi Q., Chen D., Zhu L., Wang X. A novel recombinant pseudorabies virus expressing parvovirus VP2 gene: immunogenicity and protective efficacy in swine. Virol. J. 2011, 8:307.
7. Fachinger V., Bischoff R., Jedidia S.B., Saalmuller A., Elbers K. The effect of vaccination against porcine circovirus type 2 in pigs suffering from porcine respiratory disease complex. Vaccine 2008, 26:1488-1499.
8. Fort M., Olvera A., Sibila M., Segales J., Mateu E. Detection of neutralizing antibodies in postweaning multisystemic wasting syndrome (PMWS)-affected and non-PMWS-affected pigs. Vet. Microbiol. 2007, 125:244-255.
9. Horlen K.P., Dritz S.S., Nietfeld J.C., Henry S.C., Hesse R.A., Oberst R., Hays M., Anderson J., Rowland R.R. A field evaluation of mortality rate and growth performance in pigs vaccinated against porcine circovirus type 2. J. Am. Vet. Med. Assoc. 2008, 232:906-912.
10. Huang C., Hung J.J., Wu C.Y., Chien M.S. Multiplex PCR for rapid detection of pseudorabies virus, porcine parvovirus and porcine circoviruses. Vet. Microbiol. 2004, 101:209-214.
11. Kurmann J., Sydler T., Brugnera E., Buergi E., Haessig M., Suter M., Sidler X. Vaccination of dams increases antibody titer and improves growth parameters in finisher pigs subclinically infected with porcine circovirus type 2. Clin. Vaccine Immunol. 2011, 18:1644-1649.
12. Liu L.J., Suzuki T., Tsunemitsu H., Kataoka M., Ngata N., Takeda N., Wakita T., Miyamura T., Li T.C. Efficient production of type 2 porcine circovirus-like particles by a recombinant baculovirus. Arch. Virol. 2008, 153:2291-2295.
13. Mankertz A., Mankertz J., Wolf K., Buhk H.J. Identification of a protein essential for replication of porcine circovirus. J. Gen. Virol. 1998, 79:381-384.
14. Martelli P., Ferrari L., Morganti M., De Angelis E., Bonilauri P., Guazzetti S., Caleffi A., Borghetti P. One dose of a porcine circovirus 2 subunit vaccine induces humoral and cell-mediated immunity and protects against porcine circovirus-associated disease under field conditions. Vet. Microbiol. 2011, 149:339-351.
15. Mettenleiter T.C. Aujeszky's disease (pseudorabies) virus: the virus and molecular pathogenesis-state of the art, June 1999. Vet. Res. 2000, 31:99-115.
16. Nawagitgul P., Morozov I., Bolin S.R., Harms P.A., Sorden S.D., Paul P.S. Open reading frame 2 of porcine circovirus type 2 encodes a major capsid protein. J. Gen. Virol. 2000, 81:2281-2287.
17. Noad R., Roy P. Virus-like particles as immunogens. Trends Microbiol. 2003, 11:438-444.
18. Opriessnig T., Meng X.J., Halbur P.G. Porcine circovirus type 2 associated disease: update on current terminology, clinical manifestations, pathogenesis, diagnosis, and intervention strategies. J. Vet. Diagn. Invest. 2007, 19:591-615.
19. Opriessnig T., Patterson A.R., Madson D.M., Pal N., Ramamoorthy S., Meng X.J., Halbur P.G. Comparison of the effectiveness of passive (dam) versus active (piglet) immunization against porcine circovirus type 2 (PCV2) and impact of passively derived PCV2 vaccine-induced immunity on vaccination. Vet. Microbiol. 2010, 142:177-183.
20. Pomeranz L.E., Reynolds A.E., Hengartner C.J. Molecular biology of pseudorabies virus: impact on neurovirology and veterinary medicine. Microbiol. Mol. Biol. Rev. 2005, 69:462-500.
21. Rovira A., Balasch M., Segales J., Garcia L., Plana-Duran J., Rosell C., Ellerbrok H., Mankertz A., Domingo M. Experimental inoculation of conventional pigs with porcine reproductive and respiratory syndrome virus and porcine circovirus 2. J. Virol. 2002, 76:3232-3239.
22. Segales J., Allan G.M., Domingo M. Porcine circovirus diseases. Anim. Health Res. Rev. 2005, 6:119-142.
23. Trible B.R., Kerrigan M., Crossland N., Potter M., Faaberg K., Hesse R., Rowland R.R.R. Antibody recognition of porcine circovirus type 2 capsid protein epitopes after vaccination, infection, and disease. Clin. Vaccine Immunol. 2011, 18:749-757.
24. Trible B.R., Ramirez A., Suddith A., Fuller A., Kerrigan M., Hesse R., Nietfeld J., Guo B., Thacker E., Rowland R.R. Antibody responses following vaccination versus infection in a porcine circovirus-type 2 (PCV2) disease model show distinct differences in virus neutralization and epitope recognition. Vaccine 2012, 30:4079-4085.
25. Trible B.R., Suddith A.W., Kerrigan M.A., Cino-Ozuna A.G., Hesse R.A., Rowland R.R. Recognition of the different structural forms of the capsid protein determines the outcome following infection with porcine circovirus type 2. J. Virol. 2012, 86:13508-13514.
26. Truong C., Mahe D., Blanchard P., Le Dimna M., Madec F., Jestin A., Albina E. Identification of an immunorelevant ORF2 epitope from porcine circovirus type 2 as a serological marker for experimental and natural infection. Arch. Virol. 2001, 146:1197-1211.
27. van Oirschot J.T., Kaashoek M.J., Rijsewijk F.A.M., Stegeman J.A. The use of marker vaccines in eradication of herpesviruses. J. Biotechnol. 1996, 44:75-81.
28. Wu P.C., Chien M.S., Tseng Y.Y., Lin J., Lin W.L., Yang C.Y., Huang C. Expression of the porcine circovirus type 2 capsid protein subunits and application to an indirect ELISA. J. Biotechnol. 2008, 133:58-64.
29. Wu P.C., Lin W.L., Wu C.M., Chi J.N., Chien M.S., Huang C. Characterization of porcine circovirus type 2 (PCV2) capsid particle assembly and its application to virus-like particle vaccine development. Appl. Microbiol. Biotechnol. 2012, 95:1501-1507.
30. Xu G., Xu X., Li Z., He Q., Wu B., Sun S., Chen H. Construction of recombinant pseudorabies virus expressing NS1 protein of Japanese encephalitis (SA14-14-2) virus and its safety and immunogenicity. Vaccine 2004, 22:1846-1853.